A reported Series E round for HeartFlow, estimated at $150 million, would value the company at more than $1 billion, vaulting it into unicorn territory.
Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions.
According to a Delaware regulatory filing uncovered by PitchBook and reported by Recode.net, the $25.33 per share valuation would make HeartFlow worth $1.4 billion. HeartFlow’s $99.9 million Series D valued the company at $760 million in May 2016, according to PitchBook.
Earlier this month the company won a new technology ambulatory payment classification from the Centers for Medicare & Medicaid Services.
In late August, HeartFlow said it won positive medical policies for its HeartFlow FFRct fractional flow reserve analysis system from three separate Blue Cross Blue Shield providers.